NEW QIAstat-Dx Respiratory 2019-nCoV Panel

NEW QIAstat-Dx Respiratory 2019-nCoV Panel

December 18, 2020

To support the research efforts for accessible testing to meet the demands of the COVID-19 outbreak, QIAGEN® developed the QIAstat-Dx® Respiratory 2019-nCoV Panel. This version of our multiplex syndromic cartridge detects and differentiates 22 respiratory targets, including 2019-nCoV (SARS-CoV-2).

  • Includes 2 molecular targets specific to 2019-nCoV: ORF1b gene recommended by the Chinese Center for Disease Control and Prevention, and the E gene recommended by the US Centers for Disease Control and Prevention
  • Less than 1 minute hands-on time
  • Time to result: approximately 1 hour
BRCA Tumor MASTR Plus Product launch

BRCA Tumor MASTR Plus Product launch

Multiplicom is pleased to announce the release of the BRCA Tumor MASTR Plus molecular assay, research use only, for identification of SNVs in the coding region of BRCA1 and BRCA2 in various types of solid tumors.

June 17, 2015 More +
Ready to make an enquiry Call us on: + 961 1 39 66 77
Or email us